Tilray Brands, Inc.
TLRY • NASDAQ
Tilray Brands, Inc. is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Irwin David Simon, with a market cap of $736.3M.
CEOIrwin David Simon
Next Earnings
Upcoming earnings announcement for Tilray Brands, Inc.
Date
Wednesday, April 1, 2026 (in 2 days)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q3 2026
EPS Estimate
-$0.01
Revenue Estimate
$203.2M
Earnings History
Past 12 earnings reports for Tilray Brands, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Jan 8, 2026 | Q2 2026 | $0.01Est: -$0.06 | +116.7% | $217.5MEst: $210.5M | +3.3% |  10-Q |
| Oct 9, 2025 | Q1 2026 | $0.00Est: -$0.01 | +100.0% | $209.5MEst: $206.2M | +1.6% | 10-Q |
| Jul 28, 2025 | Q4 2025 | $0.02Est: -$0.01 | +300.0% | $224.5MEst: $236.0M | -4.9% | 10-K |
| Apr 8, 2025 | Q3 2025 | $0.00Est: -$0.03 | +100.0% | $185.8MEst: $210.5M | -11.7% | 10-Q |
| Jan 10, 2025 | Q2 2025 | $0.00Est: -$0.01 | +100.0% | $211.0MEst: $216.3M | -2.5% | 10-Q |
| Oct 10, 2024 | Q1 2025 | -$0.01Est: -$0.04 | +75.0% | $200.0MEst: $219.3M | -8.8% | 10-Q |
| Jul 29, 2024 | Q4 2024 | $0.04Est: -$0.02 | +300.0% | $229.9MEst: $227.1M | +1.2% | 10-K |
| Apr 9, 2024 | Q3 2024 | $0.00Est: -$0.05 | +100.0% | $188.3MEst: $198.5M | -5.1% | 10-Q |
| Jan 9, 2024 | Q2 2024 | $0.00Est: -$0.06 | +100.0% | $193.8MEst: $195.1M | -0.7% | 10-Q |
| Oct 4, 2023 | Q1 2024 | -$0.10 | — | $176.9MEst: $174.0M | +1.7% | — |
| Jul 26, 2023 | Q4 2023 | $0.00Est: -$0.05 | +100.0% | $184.2MEst: $153.7M | +19.9% | — |
| Apr 10, 2023 | Q3 2023 | -$0.04 | — | $145.6M | — | — |